LncRNA LINC00460: Function and mechanism in human cancer

Abstract

Long non‐coding RNAs (LncRNAs), which are more than 200 nucleotides in length and with limited protein‐coding potential, play vital roles in the pathogenesis, tumorigenesis, and angiogenesis of cancers. Aberrant expression of lncRNAs has been detected in various carcinomas and may be correlated with oncogenesis by affecting related genes expression. Recently, an increasing number of studies have reported on long intergenic non‐protein coding RNA 460 (LINC00460) in human tumor fields. LINC00460 is upregulated in diverse cancer tissues and cells. The upregulated expression level of LINC00460 is correlated with larger tumor size, tumor node metastasis (TNM) stage, lymph node metastasis, and shorter overall survival. The regulatory mechanism of LINC00460 was complex and diverse. LINC00460 could act as a competitive endogenous RNA (ceRNA), directly bind with proteins or regulate multiple pathways, which affected tumor progression. Moreover, LINC00460 was also identified to increase drug resistance, and therefore, weaken the effectiveness of tumor treatment. It has become increasingly important to investigate the roles of LINC00460 in various cancers by different mechanisms. Therefore, a more comprehensive understanding of LINC00460 is crucial to expound on the cellular function and molecular mechanism of human cancers. In this review, we refer to studies concerning LINC00460 and provide the basis for the evaluation of LINC00460 as a predicted biomarker or potential therapeutic target in malignancies, and also provide ideas for the future research of lncRNAs similar to LINC00460.

Ferroptosis-associated lncRNA prognostic signature predicts prognosis and immune response in clear cell renal cell carcinoma

“…6b. According to the results of differentially expressed analysis and relevant literature [14][15][16][17] , LINC00460 and LINC00551 were www.nature.com/scientificreports/ selected for further validation. LINC00460 expression was substantially higher in ccRCC (logFC = 5.039969, P = 1.74e−19), however, LINC00551 was downregulated in ccRCC (logFC = − 3.51939, P = 1.62e−36).…”

LINC00460 Facilitates Cell Proliferation and Inhibits Ferroptosis in Breast Cancer Through the miR-320a/MAL2 Axis

“…It has been reported that LINC00460 is increased in diverse cancer tissues and is associated with clinicopathological characteristics of cancer patients. 11 For example, the expression levels of LINC00460 were increased in colorectal cancer tissues and colorectal cancer patients with high LINC00460 expression showed poor 5-year overall survival and disease-free survival. 26 In prostate cancer, LINC00460 was reported to be increased in cancer tissues, and high LINC00460 expression was correlative to tumor size and high Gleason score.…”

“… 7 – 10 Long intergenic noncoding RNA 460 (LINC00460) is located in the chr13q33.2 region and has been demonstrated to be increased in many types of solid tumors, such as colorectal cancer, hepatocellular carcinoma, lung cancer, and renal cell carcinoma. 11 The levels of LINC00460 were upregulated in the breast cancer tissues and positively associated with lymphatic metastasis and poor overall survival of patients with breast cancer. 12 Moreover, LINC00460 was identified as an oncogenic gene and promoted breast cancer progression through the miR-489-5p/Fibroblast Growth Factor 7 (FGF7)/AKT axis.…”

Comprehensive analysis of necroptosis-related long noncoding RNA to predict prognosis, immune status, and immunotherapeutic response in clear cell renal cell carcinoma

“…Aberrant expression of lncRNA is a common biological phenomenon and is closely related to the prognosis of cancers ( 37 ). LINC00460 is widely and highly expressed in human cancers and acts as a potential oncogene, which is a potential biomarker for cancer diagnosis, prognosis, and therapy ( 38 ). The correlation between lncRNAs and immune cells suggests that LINC00460 was highly and positively associated with immune status, indicating it might be the essential biomarker for the signature.…”